Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 9, 1999, Pages 2148-2155

  Petraitiene, Ruta ^a   Petraitis, Vidmantas ^a   Groll, Andreas H ^a   Candelario, Myrna ^a   Sein, Tin ^a   Bell, Aaron ^a   Lyman, Caron A ^a   McMillian, Carl L ^c   Bacher, John ^b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Office of Research Services   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; FLUCONAZOLE;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0032824392     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.9.2148     Document Type: Article

References (44)

1. Anaissie, E., G. P. Bodey, H. Kantarjian, C. David, K. Barnett, E. Bow, R. Defelice, N. Downs, T. File, G. Karam, et al. 1991. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am. J. Med. 91:142-150.
2. Anaissie, E. J., J. H. Rex, O. Uzun, and S. Vartivarian. 1998. Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med. 104:238-245.
3. Bartlett, M. S., W. L. Current, M. P. Goheen, C. J. Boylan, C. H. Lee, M. M. Shaw, S. F. Queener, and J. W. Smith. 1996. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. 40:1811-1816.
4. Cole, G. T., K. R. Seshan, M. Phaneuf, and K. T. Lynn. 1991. Chlamydospore-like cells of Candida albicans in the gastrointestinal tract of infected, immunocompromised mice. Can. J. Microbiol. 37:637-646.
5. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
6. De Bock, R. 1994. Epidemiology of invasive fungal infections in bone marrow transplantation. Bone Marrow Transplant. 14(Suppl. 5):S1-S2.
7. Debono, M., and R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48:471-497.
8. Eli Lilly & Company. 1996. LY303366 Clinical investigator's Brochure. Eli Lilly & Company, Indianapolis, Ind.
9. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida spp. Diagn. Microbiol. Infect. Dis. 26:125-131.
10. Fromtling, R. A. 1994. LY303366. Drugs Future 19:338-342.
11. Frosco, M. B., and J. F. Barret. 1998. Importance of antifungal drug-resistance: clinical significance and need for novel therapy. Exp. Opin. Invest. Drugs 7:175-197.
12. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
13. Georgopapadakou, N. H., and J. S. Tkacz. 1995. The fungal cell wall as a drug target. Trends Microbiol. 3:98-104.
14. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 455-459. Dekker, New York, N.Y.
15. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, and D. J. Friedman. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
16. Gordee, R. S., D. J. Zeckner, L. C. Howard, W. E. Alborn, Jr., and M. Debono. 1988. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann. N. Y. Acad. Sci. 544: 294-309.
17. Jafari, H. S., X. Saez-LLorens, C. Severien, F. Parras, I. Friedland, S. Rinderknecht, S. Ehrett, K. D. Olsen, C. Abramowsky, and G. H. McCracken, Jr. 1994. Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis. Antimicrob. Agents Chemother. 38:83-89.
18. Jafari, H. S., X. Saez-LLorens, E. Grimprel, J. C. Argyle, K. D. Olsen, and G. H. McCracken, Jr. 1991. Characteristics of experimental Candida albicans infection of the central nervous system in rabbits. J. Infect. Dis. 164:389-395.
19. Kauffman, C. A., S. F. Bradley, S. C. Ross, and D. R. Weber. 1991. Hepatosplenic candidiasis: successful treatment with fluconazole. Am. J. Med. 91:137-141.
20. Klepser, M. E., E. J. Ernst, M. E. Ernst, S. A. Messer, and M. A. Pfaller. 1998. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob. Agents Chemother. 42:1387-1391.
21. Krishnarao, T. V., and N. J. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
22. Kurtz, M. B., and C. M. Douglas. 1997. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35:79-86.
23. Lecciones, J. A., J. W. Lee, E. E. Navarro, F. G. Witebsky, D. Marshall, S. M. Steinberg, P. A. Pizzo, and T. J. Walsh. 1992. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Rev. Infect. Dis. 14:875-383.
24. Lee, J. W., M. A. Amantea, P. A. Francis, E. E. Navarro, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1993. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718.
25. Morrison, C. J., and D. A. Stevens. 1990. Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis. Antimicrob. Agents Chemother. 34:746-750.
26. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard. NCCLS document M27-T. National Committee for Clinical Laboratory Standards, Wayne, Pa.
27. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
28. Perfect, J. R., M. M. Hobbs, K. A. Wright, and D. T. Durack. 1989. Treatment of experimental disseminated candidiasis with cilofungin. Antimicrob. Agents Chemother. 33:1811-1812.
29. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,872), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
30. Pfaller, M. A., S. A. Messer, and S. Coffman. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:763-766.
31. Rajman, I., K. Desante, B. Hatcher, J. Hemingway, R. Lachno, S. Brooks, and M. Turik. 1997. LY303366 single intravenous dose pharmacokinetics and safety in healthy volunteers, abstr. F-74, p. 158. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
32. Rex, J. H., J. E. Bennet, and A. M. Sugar. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
33. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
34. Roilides, E., T. Sein, C. Gonzalez, C. Lyman, and T. J. Walsh. 1997. Antifungal activity of splenic, liver and pulmonary macrophages against Candida albicans and modulation by macrophage colony-stimulating factor (M-CSF), abstr. G-79, p. 280. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
35. Sarosi, G. A. 1990. Amphotericin B: still the 'gold standard' for antifungal therapy. Postgrad. Med. 88:151-152, 155-161, 165-166.
36. Slavin, M. A., B. Osborne, R. Adams, M. J. Levenstein, H. G. Schoch, A. R. Feldman, J. D. Meyers, and R. A. Bowden. 1995. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis. 171: 1545-1552.
37. Walsh, T. J., C. McEntee, and D. M. Dixon. 1987. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J. Clin. Microbiol. 25:931-932.
38. Walsh, T. J., J. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38:467-470.
39. Walsh, T. J., J. W. Lee, E. Roilides, P. Francis, J. Backer, C. A. Lyman, and P. A. Pizzo. 1992. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin. Infect. Dis. 14(Suppl. 1):139-147.
40. Walsh, T. J., J. W. Lee, P. Kelly, J. Bacher, J. Lecciones, V. Thomas, C. Lyman, D. Coleman, R. Gordee, and P. A. Pizzo. 1991. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-β-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob. Agents Chemother. 35:1321-1328.
41. Walsh, T. J., S. Aoki, F. Mechinaud, J. Backer, J. Lee, M. Rubin, and P. A. Pizzo. 1990. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J. Infect. Dis. 161:755-760.
42. Wright, W. L., and R. P. Wenzel. 1997. Nosocomial Candida. Epidemiology, transmission, and prevention. Infect. Dis. Clin. N. Am. 11:411-425.
43. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Rabb, J. Schmidtke, and W. Current. 1993. LY303366, activity against systemic aspergillosis and histoplasmosis in murine models, abstr. 364, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
44. Zhanel, G. G., J. A. Karlowsky, G. A. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.